Skip to main content
Top
Published in: Clinical and Experimental Medicine 1/2020

01-02-2020 | Hepatitis C | Original Article

Correlation analysis of hepatitis C virus core antigen and low viral loads: Can core antigen replace nucleic acid test?

Authors: Bo Feng, Rui-Feng Yang, Han-Ji Jiang, Yan-Di Xie, Hai-Ying Zhang, Qian Jin, Xu Cong, Lai Wei

Published in: Clinical and Experimental Medicine | Issue 1/2020

Login to get access

Abstract

Value of hepatitis C virus (HCV) core antigen (cAg) test has been controversy in patients with low HCV loads for its lower sensitivity. We assessed correlation between HCV-cAg and HCV RNA in serum samples with low viral loads and analyzed the performance of HCV-cAg assay in determining diagnosis and treatment outcomes in chronic hepatitis C patients. Both HCV RNA and HCV-cAg were detected for 2298 serum samples. Correlation analysis was performed between the two tests. Receiver operating characteristics (ROC) curve was used to assess value of HCV-cAg test in determining diagnosis and response outcomes at the different HCV RNA thresholds. The two tests were correlated very well, and moreover, correlation in the low viral load group was higher than that in the high viral load group (r value: 0.901 and 0.517). Positive agreement of HCV-cAg ≥ 3 fmol/L was as high as 97.0% for HCV RNA ≥ 1000 IU/mL, and its negative agreement for HCV RNA < 15 IU/mL was up to 98.9% in all samples. Area under ROCs ranged from 0.939 to 0.992, regardless of HCV RNA thresholds. When lower limit of detection of HCV RNA was 15, 100 or 1000 IU/mL, positive predictive value of HCV-cAg was 96.8%, 98.8% or 92.4%, and its negative predictive value was 87.0%, 89.9% or 98.3%, respectively, on the basis of different cutoff values. High-sensitivity HCV-cAg detection may likely replace HCV RNA to confirm the existence of HCV and to guide the treatment of chronic HCV infection.
Literature
2.
go back to reference Jiang HJ, Wang XX, Luo BF, et al. Direct antiviral agents upregulate natural killer cell potential activity in chronic hepatitis C patients. Clin Exp Med. 2019;19:299–308.CrossRef Jiang HJ, Wang XX, Luo BF, et al. Direct antiviral agents upregulate natural killer cell potential activity in chronic hepatitis C patients. Clin Exp Med. 2019;19:299–308.CrossRef
3.
go back to reference Wróblewska A, Lorenc B, Cheba M, Bielawski KP, Sikorska K. Neutrocyte-to-lymphocyte ratio predicts the presence of a replicative hepatitis C virus strand after therapy with direct-acting antivirals. Clin Exp Med. 2019;19:401–6.CrossRef Wróblewska A, Lorenc B, Cheba M, Bielawski KP, Sikorska K. Neutrocyte-to-lymphocyte ratio predicts the presence of a replicative hepatitis C virus strand after therapy with direct-acting antivirals. Clin Exp Med. 2019;19:401–6.CrossRef
5.
go back to reference Nguyen LT, Gray E, O’Leary A, Carr M, De Gascun CF. Irish hepatitis C outcomes research network. The role of hepatitis C virus core antigen testing in the era of direct acting antiviral therapies: what we can learn from the protease inhibitors. PLoS One. 2016;11:e0163900.CrossRef Nguyen LT, Gray E, O’Leary A, Carr M, De Gascun CF. Irish hepatitis C outcomes research network. The role of hepatitis C virus core antigen testing in the era of direct acting antiviral therapies: what we can learn from the protease inhibitors. PLoS One. 2016;11:e0163900.CrossRef
6.
go back to reference Jülicher P, Galli C. Identifying cost-effective screening algorithms for active hepatitis C virus infections in a high prevalence setting. J Med Econ. 2018;21:1–10.CrossRef Jülicher P, Galli C. Identifying cost-effective screening algorithms for active hepatitis C virus infections in a high prevalence setting. J Med Econ. 2018;21:1–10.CrossRef
7.
go back to reference Takahashi K, Okamoto H, Kishimoto S, et al. Demonstration of a hepatitis C virus-specific antigen predicted from the putative core gene in the circulation of infected hosts. J Gen Virol. 1992;73:667–72.CrossRef Takahashi K, Okamoto H, Kishimoto S, et al. Demonstration of a hepatitis C virus-specific antigen predicted from the putative core gene in the circulation of infected hosts. J Gen Virol. 1992;73:667–72.CrossRef
8.
go back to reference Freiman JM, Tran TM, Schumacher SG, et al. Hepatitis C core antigen testing for diagnosis of hepatitis C virus infection: a systematic review and meta-analysis. Ann Intern Med. 2016;165:345–55.CrossRef Freiman JM, Tran TM, Schumacher SG, et al. Hepatitis C core antigen testing for diagnosis of hepatitis C virus infection: a systematic review and meta-analysis. Ann Intern Med. 2016;165:345–55.CrossRef
9.
go back to reference Chang C, Hung CH, Wang JH, Lu SN. Hepatitis C core antigen highly correlated to HCV RNA. Kaohsiung J Med Sci. 2018;34:684–8.CrossRef Chang C, Hung CH, Wang JH, Lu SN. Hepatitis C core antigen highly correlated to HCV RNA. Kaohsiung J Med Sci. 2018;34:684–8.CrossRef
10.
go back to reference Cetiner S, Duran AC, Kibar F, Yaman A. Performance comparison of new generation HCV core antigen test versus HCV RNA test in management of hepatitis C virus infection. Transfus Apher Sci. 2017;56:362–6.CrossRef Cetiner S, Duran AC, Kibar F, Yaman A. Performance comparison of new generation HCV core antigen test versus HCV RNA test in management of hepatitis C virus infection. Transfus Apher Sci. 2017;56:362–6.CrossRef
11.
go back to reference Lamoury FMJ, Hajarizadeh B, Soker A, et al. Evaluation of a hepatitis C virus core antigen assay in plasma and dried blood spot samples. J Mol Diagn. 2018;20:621–7.CrossRef Lamoury FMJ, Hajarizadeh B, Soker A, et al. Evaluation of a hepatitis C virus core antigen assay in plasma and dried blood spot samples. J Mol Diagn. 2018;20:621–7.CrossRef
12.
go back to reference Feng B, Yang RF, Zhang HY, et al. Early predictive efficacy of core antigen on antiviral outcomes in genotype 1 hepatitis C virus infected patients. Braz J Infect Dis. 2015;19:390–8.CrossRef Feng B, Yang RF, Zhang HY, et al. Early predictive efficacy of core antigen on antiviral outcomes in genotype 1 hepatitis C virus infected patients. Braz J Infect Dis. 2015;19:390–8.CrossRef
13.
go back to reference European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatitis C virus infection. J Hepatol. 2014;60:392–420.CrossRef European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatitis C virus infection. J Hepatol. 2014;60:392–420.CrossRef
14.
go back to reference Ghanbari K, Roushani M, Azadbakht A. Ultra-sensitive aptasensor based on a GQD nanocomposite for detection of hepatitis C virus core antigen. Anal Biochem. 2017;534:64–9.CrossRef Ghanbari K, Roushani M, Azadbakht A. Ultra-sensitive aptasensor based on a GQD nanocomposite for detection of hepatitis C virus core antigen. Anal Biochem. 2017;534:64–9.CrossRef
15.
go back to reference Pleshakova TO, Kaysheva AL, Bayzyanova JM, et al. The detection of hepatitis C virus core antigen using afm chips with immobolized aptamers. J Virol Methods. 2018;251:99–105.CrossRef Pleshakova TO, Kaysheva AL, Bayzyanova JM, et al. The detection of hepatitis C virus core antigen using afm chips with immobolized aptamers. J Virol Methods. 2018;251:99–105.CrossRef
16.
go back to reference Pleshakova TO, Kaysheva AL, Shumov ID, et al. Detection of hepatitis C virus core protein in serum using aptamer-functionalized AFM chips. Micromach Basel. 2019;10:129.CrossRef Pleshakova TO, Kaysheva AL, Shumov ID, et al. Detection of hepatitis C virus core protein in serum using aptamer-functionalized AFM chips. Micromach Basel. 2019;10:129.CrossRef
17.
go back to reference Murdaca G, Contini P, Cagnati P, et al. Behavior of soluble HLA-A, -B, -C and HLA-G molecules in patients with chronic hepatitis C virus infection undergoing pegylated interferon-α and ribavirin treatment: potential role as markers of response to antiviral therapy. Clin Exp Med. 2017;17:93–100.CrossRef Murdaca G, Contini P, Cagnati P, et al. Behavior of soluble HLA-A, -B, -C and HLA-G molecules in patients with chronic hepatitis C virus infection undergoing pegylated interferon-α and ribavirin treatment: potential role as markers of response to antiviral therapy. Clin Exp Med. 2017;17:93–100.CrossRef
18.
go back to reference European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2018. J Hepatol. 2018;69:461–511.CrossRef European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2018. J Hepatol. 2018;69:461–511.CrossRef
19.
go back to reference AASLD/IDSA HCV Guidance Panel. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology. 2015;62:932–54.CrossRef AASLD/IDSA HCV Guidance Panel. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology. 2015;62:932–54.CrossRef
20.
go back to reference Terrault NA, Pawlotsky JM, McHutchison J, et al. Clinical utility of viral load measurements in individuals with chronic hepatitis C infection on antiviral therapy. J Viral Hepat. 2005;12:465–72.CrossRef Terrault NA, Pawlotsky JM, McHutchison J, et al. Clinical utility of viral load measurements in individuals with chronic hepatitis C infection on antiviral therapy. J Viral Hepat. 2005;12:465–72.CrossRef
21.
go back to reference Ticehurst JR, Hamzeh FM, Thomas DL. Factors affecting serum concentrations of hepatitis C virus (HCV) RNA in HCV genotype 1-infected patients with chronic hepatitis. J Clin Microbiol. 2007;45:2426–33.CrossRef Ticehurst JR, Hamzeh FM, Thomas DL. Factors affecting serum concentrations of hepatitis C virus (HCV) RNA in HCV genotype 1-infected patients with chronic hepatitis. J Clin Microbiol. 2007;45:2426–33.CrossRef
22.
go back to reference Arboledas JCA, Guerrero IP, Rodríguez MJB, et al. Hepatitis C virus core antigen in the management of patients treated with new direct-acting antivirals. Diagn Microbiol Infect Dis. 2017;89:29–34.CrossRef Arboledas JCA, Guerrero IP, Rodríguez MJB, et al. Hepatitis C virus core antigen in the management of patients treated with new direct-acting antivirals. Diagn Microbiol Infect Dis. 2017;89:29–34.CrossRef
23.
go back to reference Kuo YH, Chang KC, Wang JH, et al. Is hepatitis C virus core antigen an adequate marker for community screening? J Clin Microbiol. 2012;50:1989–93.CrossRef Kuo YH, Chang KC, Wang JH, et al. Is hepatitis C virus core antigen an adequate marker for community screening? J Clin Microbiol. 2012;50:1989–93.CrossRef
24.
go back to reference Medici MC, Furlini G, Rodella A, et al. Hepatitis C virus core antigen: analytical performances, correlation with viremia and potential applications of a quantitative, automated immunoassay. J Clin Virol. 2011;51:264–9.CrossRef Medici MC, Furlini G, Rodella A, et al. Hepatitis C virus core antigen: analytical performances, correlation with viremia and potential applications of a quantitative, automated immunoassay. J Clin Virol. 2011;51:264–9.CrossRef
25.
go back to reference Miedouge M, Saune K, Kamar N, Rieu M, Rostaing L, Izopet J. Analytical evaluation of HCV core antigen and interest for HCV screening in haemodialysis patients. J Clin Virol. 2010;48:18–21.CrossRef Miedouge M, Saune K, Kamar N, Rieu M, Rostaing L, Izopet J. Analytical evaluation of HCV core antigen and interest for HCV screening in haemodialysis patients. J Clin Virol. 2010;48:18–21.CrossRef
Metadata
Title
Correlation analysis of hepatitis C virus core antigen and low viral loads: Can core antigen replace nucleic acid test?
Authors
Bo Feng
Rui-Feng Yang
Han-Ji Jiang
Yan-Di Xie
Hai-Ying Zhang
Qian Jin
Xu Cong
Lai Wei
Publication date
01-02-2020
Publisher
Springer International Publishing
Keyword
Hepatitis C
Published in
Clinical and Experimental Medicine / Issue 1/2020
Print ISSN: 1591-8890
Electronic ISSN: 1591-9528
DOI
https://doi.org/10.1007/s10238-019-00588-1

Other articles of this Issue 1/2020

Clinical and Experimental Medicine 1/2020 Go to the issue